Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target remains the same with $75.00.

In this article, we are going to take a look at where Sarepta Therapeutics ... such an outcome could result in investors paying too high a price for stocks relative to their earnings potential ...

Shares of NASDAQ SRPT opened at $111.82 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The firm’s 50-day moving average is $121.12 and its 200-day ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...

Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with the potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

January 13, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year ...